227751-46-4

Usage

Chemical class

Naphthyridine derivatives 1,8-Naphthyridine-2-pentanoic acid methyl ester belongs to a group of chemical compounds derived from naphthyridine, a type of fused heterocyclic compound.

Formation

Esterification reaction 1,8-Naphthyridine-2-pentanoic acid methyl ester is formed by the reaction between 1,8-Naphthyridine-2-pentanoic acid and methanol, resulting in the formation of an ester.

Functional groups

Ester, carboxylic acid, and aromatic ring The molecule contains an ester functional group (-COOCH3), a carboxylic acid group (-COOH), and an aromatic ring structure.

Application

Organic synthesis 1,8-Naphthyridine-2-pentanoic acid methyl ester is used as a building block in the synthesis of various pharmaceutical and agrochemical compounds.

Potential uses

Biological activities and pharmacological properties 1,8-Naphthyridine-2-pentanoic acid methyl ester may have potential biological activities and is being studied for its pharmacological properties.

Stability

Stable compound The methyl ester form of the compound is stable and can be used in various chemical reactions and processes.

Solubility

Soluble in organic solvents This ester is likely to be soluble in organic solvents such as ethanol, methanol, and dichloromethane, due to its nonpolar nature.

Reactivity

Reactive towards nucleophiles and acids The ester functional group in the molecule can undergo hydrolysis in the presence of nucleophiles or acids, leading to the formation of the corresponding carboxylic acid or other products.

Structural features

Fused heterocyclic ring system The naphthyridine core consists of a fused six-membered and five-membered nitrogen-containing heterocycle, which contributes to the compound's unique properties and reactivity.

Synthesis

Multi-step process The synthesis of 1,8-Naphthyridine-2-pentanoic acid methyl ester typically involves a multi-step process, starting from simpler precursors and building up the complex structure through various chemical reactions.

Upstream product

• 7521-41-7 2-Aminonicotinaldehyde 
• 2046-21-1 methyl 6-oxoheptanoate 
• 609-36-9 rac-Pro-OH 
• 3128-07-2 6-oxoheptanoic acid 

Downstream Products

• 227751-47-5 5-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-pentanoic acid methyl ester 

Relevant academic research and scientific papers

Non-peptide αvβ3 antagonists. Part 4: Potent and orally bioavailable chain-shortened RGD mimetics

Potent non-peptidic αvβ3 antagonists have been prepared where deletion of an amide bond from an earlier series of linear RGD-mimetics provides a novel series of chain-shortened αvβ3 antagonists with significantly improved oral pharmacokinetics. These chain-shortened αvβ3 antagonists represent structurally novel integrin inhibitors.

Pyrrolidine integrin regulator and application thereof

Disclosed are a compound as represented by formula I, and a racemate, a stereoisomer, a tautomer, an isotopic marker, a nitrogen oxide, a solvate, a polymorph, a metabolite, an ester, and a prodrug thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising same, a preparation method therefor, and the medical use thereof. The structure of formula I is as follows:

RNAI AGENTS FOR INHIBITING EXPRESSION OF HIF-2 ALPHA (EPAS1), COMPOSITIONS THEREOF, AND METHODS OF USE

The present disclosure relates to RNAi agents, for example, double stranded RNAi agents, able to inhibit HIF-2 alpha ( EPAS1 ) gene expression. Also disclosed are pharmaceutical compositions that include HIF-2 alpha RNAi agents and methods of use thereof. The HIF-2 alpha RNAi agents disclosed herein may be linked or conjugated to targeting ligands (such as compounds that have affinity for integrins, including alpha-v-beta-3 and alpha-v-beta-5 integrins) and pharmacokinetic (PK) enhancers, to facilitate the delivery to cells and tissues, including to clear cell renal cell carcinoma (ccRCC) cells and tumors. Delivery of compositions comprising the HIF-2 alpha RNAi agents in vivo provides for inhibition of HIF-2 alpha gene expression. The HIF-2 alpha RNAi agents can be used in methods of treatment of various diseases and disorders, including ccRCC.

INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN

Disclosed are small molecule inhibitors of αvβ6 integrin, and methods of using them to treat a number of diseases and conditions.

INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN

Disclosed are small molecule inhibitors of ανβ6 integrin, and methods of using them to treat a number of specific diseases or conditions.

METHOD FOR MANUFACTURING NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF AND MANUFACTURING INTERMEDIATE OF NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF

Provided are a method for efficiently manufacturing a nitrogen-containing compound, which is used for manufacturing a treatment agent for integrin-related diseases, or a salt thereof and a manufacturing intermediate of the compound or a salt thereof. A me

N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE

The invention relates to compounds of formula (I), or a salt thereof wherein R1, A, L, and R2 and n are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are ανβ1 integrin inhibitors that are useful for treating tissue specific fibrosis.

NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF

The present invention provides a compound represented by the formula (1) or a salt thereof, or a complex of the compound or the salt with a metal, in the formula (1), A1 represents a chelate group; R1 represents a hydrogen atom or the like; R2 represents a hydrogen atom or the like; and Z1, Z2, Z3, Z4, and Z5 are the same or different and each represent a nitrogen atom or CR3 or the like wherein R3 represents a hydrogen atom or an optionally substituted C1-6 alkyl group or the like; L1 represents a group represented by the formula (3) wherein R13, R14, R15, and R16 are the same or different and each represent a hydrogen atom or the like; L2 represents an optionally substituted C1-6 alkylene group; and L3 represents an optionally substituted C1-6 alkylene group.

COMPOSITION AND METHODS FOR TREATING CHRONIC KIDNEY DISEASE

This invention relates to the treatment of chronic kidney disease, including diabetic nephropathy, focal segmental glomerulosclerosis (FSGS), nephrotic syndrome, non-diabetic chronic kidney disease, renal fibrosis or acute kidney injury by the administrat

TREATMENT AGENT FOR DIAGNOSIS OR TREATMENT OF DISEASE ASSOCIATED WITH INTEGRIN

PROBLEM TO BE SOLVED: To provide a treatment agent for diagnosis or treatment of disease associated with integrin. SOLUTION: A treatment agent comprises a complex of a compound represented by formula (1) or salt thereof and metal. In the formula (1), A1 is a chelate group; R1 and R2 independently represent H, alkyl, or an amino protective group; Z1-Z5 independently represent N or CR3; R3 is H or a substituted/unsubstituted C1-6 alkyl group or the like; L1 is a group represented by formula (3); L2 and L3 independently represent a substituted/unsubstituted C1-6 alkylene group. In the formula (3), R13-R16 independently represent H, alkyl or the like. SELECTED DRAWING: None COPYRIGHT: (C)2017,JPOandINPIT